Jonathan Levitt of Frier Levitt said three federal lawsuits allege CVS Health entities diverted approximately $250 million in 340B program savings from hospitals. Read More »

Anne McDonald Pritchett said that pharmacy benefit managers—not patents—are limiting patient access to lower-cost biosimilars through their business practices. Read More »

Paragon Health Institute called attention to ACA-driven expansion of hospital eligibility for the federal 340B drug pricing program. Read More »

Joe Grogan of USC Schaeffer Center said Congress must act on what he described as an out-of-control 340B drug pricing program. Read More »

Rep. Diana Lynn Harshbarger called for greater transparency in the pharmacy benefit manager industry on May 18. Read More »

PhRMA has launched an ad campaign highlighting how large nonprofit hospitals profit from 340B drug markups. Read More »

PhRMA announced support for a claims-level verified rebate model for the federal 340B drug pricing program on April 20. Read More »

Empower Pharmacy is relocating its operations from New Jersey to Houston following a lawsuit by Eli Lilly over compounded tirzepatide. Read More »

The article discusses concerns raised by Dutch Rojas about the dominance of a few insurers and PBMs in U.S. healthcare markets. Read More »

The God Particle, a trader on the social media platform X, said that legal precedent and federal law do not permit companies to sue compounding pharmacies over practices allowed under Section 503A of the Food, Drug, and Cosmetic Act. Read More »

Shaun Noorian, Founder and Chief Executive Officer of Empower Pharmacy, said on LinkedIn that the company’s direct and transparent approach eliminates unnecessary middlemen to deliver affordable medication. Read More »

Shaun Noorian, founder and CEO of Empower Pharmacy, said that the rise of personalized medicine and national pharmacy networks is driving renewed demand for pharmaceutical compounding. Read More »

Empower Clinic Services LLC, a compounding pharmacy based in Houston, has petitioned the U.S. Patent Trial and Appeal Board (PTAB) to invalidate Eli Lilly & Co. Read More »

Monty's Home Medical has announced that compounded pharmaceuticals offer a customized solution to patient care by adjusting medications to individual needs, including dosage, form, and ingredients, for safer and more effective treatment. Read More »

The Kaiser Family Foundation (KFF) has released findings on the affordability challenges faced by U.S. adults regarding GLP-1 drugs, revealing significant cost concerns even among those with insurance coverage. Read More »

National Healthcareer Association (NHA) is now partnering with CEimpact to offer pharmacy technicians an ACPE-accredited immunization training option, helping them qualify to administer vaccinations according to the U.S. Department of Health and Human Services' (HHS) Public Readiness and Emergency Preparedness (PREP) Act. Read More »

Managing receivables from Insurance becomes easier for Pharmacies Read More »

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis (ALS). Read More »

The highly attended virtual trade show series for pharmaceutical manufacturing professionals is returning for two installments in 2021. Read More »

Pharmacists "Again Prepared to Step Forward and Serve as Essential Health Care Providers" Read More »